1. Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective

   • Ennio Lubrano
   • Silvia Scriffignano
   • Fabio Massimo Perrotta

   Commentary Open access 10 December 2022 Pages: 301 - 306

   

2. Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons

   • Nurullah Akkoç
   • Carlos H. Arteaga
   • Philip J. Mease

   Review Open access 12 January 2023 Pages: 307 - 327

   

3. Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data

   • Wan-Hee Yoo
   • Young Mo Kang
   • Jung-Yoon Choe

   Original Research Open access 08 December 2022 Pages: 329 - 341

   

4. A Streamlined Diagnostic Process Improved the Outcomes of Patients with Adult-Onset Still’s Disease: A Single-Center Retrospective Observational Study

   • Shih-Hsin Chang
   • Teng-Chieh Hsu
   • Der-Yuan Chen

   Original Research Open access 10 December 2022 Pages: 343 - 355

   

5. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

   • Kevin L. Winthrop
   • Arne Yndestad
   • Stanley B. Cohen

   Original Research Open access 17 December 2022 Pages: 357 - 373

   

6. Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate

   • Roy Fleischmann
   • Boulos Haraoui
   • Kristen Lee

   Original Research Open access 19 December 2022 Pages: 375 - 386

   

7. Serious Infection Rates Among Patients with Select Autoimmune Conditions: A Claims-Based Retrospective Cohort Study from Taiwan and the USA

   • Wen-Nan Huang
   • Ching-Yi Chuo
   • Lisa Lindsay

   Original Research Open access 26 December 2022 Pages: 387 - 404

   

8. Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience

   • Wenhui Xie
   • Hong Huang
   • Zhuoli Zhang

   Original Research Open access 06 January 2023 Pages: 405 - 419

   

9. Number of Attending Physicians and Accumulated Organ Damage in Patients with Systemic Lupus Erythematosus: LUNA Registry Cross-Sectional Study

   • Ryo Yanai
   • Nobuyuki Yajima
   • Ken-ei Sada

   Original Research Open access 06 January 2023 Pages: 421 - 431

   

10. Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries

    • Peter C. Taylor
    • Yuri Sanchez Gonzalez
    • Oliver Howell

    Original Research Open access 12 January 2023 Pages: 433 - 445

    

11. Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study

    • Christopher F. Bell
    • Jake Chung
    • Bernard Rubin

    Original Research Open access 18 January 2023 Pages: 447 - 462

    

12. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies

    • Peter C. Taylor
    • Yun-Fei Chen
    • Yoshiya Tanaka

    Original Research Open access 20 January 2023 Pages: 463 - 476

    

13. High Usability and Applicability Ratings for the New SmartClic^®/ClicWise^® Injection Device: Evidence from a Health Care Professional Opinion Study

    • Rieke Alten
    • Simon Moss
    • Mark Latymer

    Original Research Open access 22 January 2023 Pages: 477 - 487

    

14. PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis

    • Stefan Siebert
    • Frank Behrens
    • Laure Gossec

    Study Protocol Open access 30 December 2022 Pages: 489 - 505